Jun 02, 2022 / NTS GMT
Søren Bregenholt - Alligator Bioscience AB - CEO
Hi. I'm Søren Bregenholt. I'm the CEO of Alligator Bioscience. It's a pleasure being with you today. So Alligator Bioscience is a clinical-stage biotech company with a deep and broad pipeline in best-in-class, both monoclonal and bispecific, antibodies and a range of novel monoclonal bispecific antibody technologies. We are listed on NASDAQ in Stockholm and headquartered in Lund in the southern part of Sweden.
Our lead asset, mitazalimab, is being developed in first-line pancreatic cancer in combination with chemotherapy. And we are currently conducting a Phase II study here. In addition, we have a differentiated pipeline with several near- to mid-term value drivers. And our leading antibody technologies are well positioned to sustain longer-term value generation for Alligator. In addition, we have several pipeline assets that are mature for out-licensing.
We built a strong team with a proven track record for global biotech and pharma, making us well suited to deliver both in product development, on operational execution of
Alligator Bioscience AB at Redeye Growth Day (Virtual) Transcript
Jun 02, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers